Immunological Characteristics of the Putative CD4-Binding Site of the HIV-1 Envelope protein

Kieber‐Emmons, Thomas; Krowka, John F.; Boyer, Jean Z.; Ugen, Ken; Williams, William V.; Morrow, W. J. W.; Weiner, D. B.

doi:10.1159/000163722

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIV components such as gp120 or gp160 have multiple effects on lymphocytes including polyclonal B cell activation and enhancement of IL-6 secretion [19-211, suppression of lymphocyte proliferation to recall antigens [30] and suppression of helper cell functions [31]. These HIV-derived glycoproteins may also affect T-dependent B cell functions.…”

Section: Discussionmentioning

confidence: 99%

In vitro Cytokine Treatment of B Cell Defects in HIV‐Infected Hemophilia Patients

et al. 1995

View full text Add to dashboard Cite

HIV-infected patients exhibit defects in B cell differentiation and in the IL-6 response of B cells, in association with autoantibody formation against T cells. These autoantibodies have been implicated as important factors in the development of immunodeficiency disease. As the restoration of defective B cell responses might prevent autoantibody formation and the resulting immunosuppression, we studied whether in vitro treatment with recombinant IL-2 (rIL-2), recombinant IL-4 (rIL-4) or recombinant IL-6 (rIL-6) might restore the response of B cells of HIV-infected patients. B cells of 6 HIV-negative hemophilia patients, 4 HIV-positive patients at CDC stage II, III, 4 HIV-positive patients at CDC stage IV, and 6 healthy controls were tested in Staphylococcus aureus Cowan I (SAC-I)-stimulated B cell cultures and Pokeweed mitogen (PWM)-stimulated allogeneic B and T cell cocultures. B cell differentiation was assessed in a reverse hemolytic plaque assay and by ELISA determination of IgM, IgG and IL-6 in culture supernatants. In vitro application of rIL-6 resulted in suppression of both elevated unstimulated and mitogen-stimulated B cell responses in a dose-dependent manner which was in part due to feedback inhibition. PWM- and SAC-I-stimulated IgG and IgM responses, respectively, could be restored after addition of 10 U/ml rIL-2 in HIV-negative patients, but not in HIV-positive patients. Addition of rIL-4 to cultures resulted in suppression of both unstimulated and mitogen-stimulated IL-6 secretion and B cell responses. Severely depressed B cell responses in CDC IV patients were not significantly affected by cytokine application. These results indicate that defective Ig responses in HIV-negative patients may be restored by rIL-2 treatment whereas HIV-induced B cell defects are not corrected by supply of T cell help or cytokines promoting B cell growth and differentiation.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro Cytokine Treatment of B Cell Defects in HIV‐Infected Hemophilia Patients

et al. 1995

View full text Add to dashboard Cite

show abstract

“…HIV components such as gpl20 or gpl60 have multiple effects on lymphocytes including polyclonal B cell activa tion and enhancement of IL-6 secretion [19][20][21], suppres sion of lymphocyte proliferation to recall antigens [30] and suppression of helper cell functions [31]. These HIV-derived glycoproteins may also affect T-dependent B cell functions.…”

Section: Il-4 Addition In Vitromentioning

confidence: 99%

In vitro Cytokine Treatment of B Cell Defects in HIV-lnfected Hemophilia Patients

Weimer¹,

Zipperle²,

Daniel³

et al. 1995

Vox Sanguinis

View full text Add to dashboard Cite

HIV-infected patients exhibit defects in B cell differentiation and in the IL-6 response of B cells, in association with autoantibody formation against T cells. These autoantibodies have been implicated as important factors in the development of immunodeficiency disease. As the restoration of defective B cell responses might prevent autoantibody formation and the resulting immunosuppression, we studied whether in vitro treatment with recombinant IL-2 (rIL-2), recombinant IL-4 (rIL-4) or recombinant IL-6 (rIL-6) might restore the response of B cells of HIV-infected patients. B cells of 6 HIV-negative hemophilia patients, 4 HIV-positive patients at CDC stage II,III, 4 HIV-positive patients at CDC stage IV, and 6 healthy controls were tested in Staphylococcus aureus Cowan I (SAC-I)-stimulated B cell cultures and Pokeweed mitogen (PWM)-stimulated allogeneic B and T cell cocultures. B cell differentiation was assessed in a reverse hemolytic plaque assay and by ELISA determination of IgM, IgG and IL-6 in culture supernatants. In vitro application of rIL-6 resulted in suppression of both elevated unstimulated and mitogen-stimulated B cell responses in a dose-de- pendent manner which was in part due to feedback inhibition. PWM- and SAC-I- stimulated IgG and IgM responses, respectively, could be restored after addition of 10 U/ml rIL-2 in HIV-negative patients, but not in HIV-positive patients. Addition of rIL-4 to cultures resulted in suppression of both unstimulated and mitogen-stimulated IL-6 secretion and B cell responses. Severely depressed B cell responses in CDC IV patients were not significantly affected by cytokine application. These results indicate that defective Ig responses in HIV-negative patients may be restored by rIL-2 treatment whereas HIV-induced B cell defects are not corrected by supply of T cell help or cytokines promoting B cell growth and differentiation.

show abstract

Immunological Characteristics of the Putative CD4-Binding Site of the HIV-1 Envelope protein

Cited by 2 publications

References 7 publications

In vitro Cytokine Treatment of B Cell Defects in HIV‐Infected Hemophilia Patients

In vitro Cytokine Treatment of B Cell Defects in HIV‐Infected Hemophilia Patients

In vitro Cytokine Treatment of B Cell Defects in HIV-lnfected Hemophilia Patients

Contact Info

Product

Resources

About